HGH FDA Approved

What It Is

Human growth hormone (hGH, somatropin) is a 191-amino-acid single-chain polypeptide hormone produced by somatotroph cells of the anterior pituitary gland and released in pulsatile bursts under the combined control of hypothalamic growth-hormone-releasing hormone (GHRH), ghrelin, and the inhibitory somatostatin. It is the master anabolic and body-composition hormone of vertebrate physiology — driving linear growth during childhood and adolescence, maintaining lean body mass and bone density during adulthood, and regulating lipid metabolism, glucose handling, and tissue repair across the lifespan.

Recombinant human GH (rhGH, somatropin) has been commercially available since 1985, when Genentech launched Protropin (methionyl-rhGH produced in E. coli) as a replacement for pituitary-extracted cadaveric GH following the recognition of Creutzfeldt-Jakob disease transmission in the cadaveric supply. Modern commercial rhGH is sequence-identical to endogenous 22 kilodalton human GH — 191 amino acids, two intrachain disulfide bonds, molecular weight 22,125 daltons. It is produced in E. coli (most brands) or in mouse-cell mammalian expression systems (Saizen), purified to pharmaceutical grade, and supplied as lyophilized powder or pre-formulated solution in multi-dose pen devices (Genotropin Pen, NordiPen, HumatroPen, Saizen easypod) or single-use vials.

Approved brands on the US market as of April 2026 include Genotropin (Pfizer), Norditropin (Novo Nordisk), Humatrope (Lilly), Omnitrope (Sandoz — the first US rhGH biosimilar approved in 2006), Saizen (EMD Serono), and Zomacton (Ferring). Long-acting / weekly rhGH formulations — Skytrofa (lonapegsomatropin; Ascendis) approved 2021 for pediatric GHD and Sogroya (somapacitan; Novo Nordisk) approved 2020 for adult GHD and 2023 for pediatric GHD — are bioengineered for sustained delivery rather than daily injection. The weekly products represent the most significant pharmaceutical change in the rhGH landscape in two decades.

FDA-approved indications for daily somatropin encompass pediatric GH deficiency (including idiopathic GHD, growth failure from chronic kidney disease, Turner syndrome, Prader-Willi syndrome, SHOX deficiency, idiopathic short stature, Noonan syndrome, and short-gestation SGA without catch-up growth), adult GH deficiency (confirmed by GH stimulation testing), AIDS-associated wasting, and short bowel syndrome (Zorbtive, higher-dose). Adult anti-aging and body-composition use is not an FDA-approved indication; it is off-label prescribing when performed within a legitimate medical relationship, and is the subject of the non-medical-distribution prohibition in 21 USC §333(e) (the "Anabolic Steroid Control Act" GH provision).

Mechanism of Action

GH's pharmacology follows directly from its dimerization-induced activation of the transmembrane GH receptor (GHR) and downstream canonical and non-canonical signaling cascades. The apparent phenotype — lean-mass gain, fat-mass reduction, tissue repair, insulin antagonism — is the composite of direct GHR signaling in target tissues plus indirect effects mediated by hepatic IGF-1 (the "somatomedin hypothesis").

• GH receptor homodimerization — GH engages two copies of the cell-surface GH receptor (GHR, a type I cytokine receptor) with 1:2 stoichiometry, inducing conformational rearrangement of pre-formed GHR homodimers and activating the constitutively-associated JAK2 tyrosine kinase (Brown et al., Nat Struct Mol Biol 2005; PMID 15834426).
• JAK2/STAT5 canonical signaling — JAK2 phosphorylates GHR cytoplasmic tyrosines, creating STAT5a/b docking sites. Phosphorylated STAT5 dimerizes, translocates to the nucleus, and drives transcription of IGF-1, ALS (acid-labile subunit), IGFBP-3, SOCS family members, and metabolic target genes. STAT5 is the single most important downstream effector for GH's somatomedin (IGF-1) effects.
• Secondary pathways — MAPK/ERK, PI3K/Akt — GHR signaling also engages Ras-Raf-MEK-ERK and PI3K-Akt cascades, mediating cell proliferation, survival, and glucose handling. Cross-talk with insulin signaling occurs at the insulin receptor substrate (IRS) level, partly explaining GH's counter-regulatory insulin-antagonistic effects.
• Hepatic IGF-1 production — Liver is the dominant source of circulating IGF-1 (~75%). GH-STAT5 signaling drives hepatic IGF-1 transcription; IGF-1 combines with IGFBP-3 and ALS to form the ternary 150 kDa circulating complex that extends IGF-1 half-life from minutes to hours. IGF-1 is the principal mediator of GH's growth-promoting effects; GH-deficient patients given IGF-1 (mecasermin) recover most but not all of the GH-driven phenotype.
• Direct lipolysis — GH directly activates hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) in adipocytes independent of IGF-1, mobilizing free fatty acids and reducing visceral and subcutaneous adipose mass. The lipolytic effect is the earliest and most consistent body-composition signature of GH therapy — evident within 2–4 weeks of starting replacement.
• Protein-sparing / nitrogen retention — GH increases whole-body protein synthesis and reduces protein oxidation, producing net positive nitrogen balance. Amino acids are redirected into lean tissue rather than gluconeogenesis — the classical anabolic phenotype.
• Counter-regulatory (insulin-antagonistic) — GH opposes insulin action in liver and muscle, increasing hepatic glucose output and reducing peripheral glucose uptake. Fasting insulin and glucose rise at higher GH doses. This is the dominant dose-limiting toxicity in adult replacement and the mechanism behind "GH gut" when combined with insulin in bodybuilding protocols.
• Bone and collagen — Direct effects on osteoblasts and indirect IGF-1-mediated effects increase bone formation and remodeling. GH is among the most potent stimulators of type I collagen synthesis — the basis of improved skin, tendon, ligament, and connective-tissue quality during replacement.
• Sleep architecture — Endogenous GH secretion is concentrated in slow-wave sleep; exogenous replacement (particularly evening dosing) interacts with sleep architecture and is often reported to enhance deep-sleep quality.
• Negative feedback — Elevated IGF-1 feeds back on hypothalamus (stimulating somatostatin) and pituitary (suppressing GHRH-driven GH release), shutting down endogenous GH. Exogenous rhGH therefore suppresses endogenous GH secretion for the duration of therapy; recovery typically occurs over weeks after cessation.
• Short-loop feedback to IGF-1 — Circulating IGF-1 from hepatic production also inhibits hepatic IGF-1 transcription at high levels — a self-limiting feature of long-term GH therapy that requires IGF-1-guided titration rather than fixed dosing.

What the Research Shows

The rhGH evidence base spans four decades of controlled trials in GH-deficient populations plus a parallel literature on off-label anti-aging and body-composition use in GH-sufficient adults. Evidence quality diverges sharply between these two domains.

• Pediatric GH deficiency — registrational pediatric trials — rhGH at 0.16–0.3 mg/kg/week SubQ produces durable height velocity acceleration and final adult height recovery in children with confirmed GHD. FDA approval basis dates to 1985 (Protropin) and has been expanded across brands. Safety profile in pediatric populations is well-characterized through the Kabi International Growth Study (KIGS) and National Cooperative Growth Study (NCGS) post-marketing registries.
• Adult GH deficiency (Molitch et al., J Clin Endocrinol Metab 2011; PMID 21543432) — Endocrine Society clinical practice guideline synthesizing two decades of adult GHD trial data. rhGH replacement in confirmed adult GHD (GH stimulation test failure in appropriate clinical context) normalizes body composition (visceral fat reduction, lean-mass gain), improves bone density, exercise capacity, lipid profile, and quality of life measures (QoL-AGHDA). Recommended starting dose 0.2 mg/day titrated to age- and sex-appropriate IGF-1.
• Rudman NEJM 1990 (PMID 2355952) — Landmark 12-subject 6-month RCT in healthy older men (60+ years) with low-IGF-1. rhGH 0.03 mg/kg SubQ 3×/week produced 8.8% increase in lean body mass, 14.4% decrease in fat mass, and 1.6% increase in lumbar spine bone density. The study that launched the anti-aging GH industry — and the study whose generalizability to healthy GH-sufficient adults has been debated ever since.
• Liu et al. systematic review (Ann Intern Med 2007; PMID 17200260) — 31 controlled studies of rhGH in healthy older adults. Meta-analytic body-composition benefit: lean mass +2.1 kg, fat mass −2.1 kg. No consistent benefit on muscle strength, bone density, or functional status. Substantially higher adverse event rates (soft tissue edema, arthralgia, carpal tunnel, gynecomastia, impaired glucose tolerance). The most cited independent appraisal of anti-aging GH.
• Weekly rhGH pediatric GHD (Thornton et al., J Clin Endocrinol Metab 2021) — heiGHt phase 3 trial of lonapegsomatropin (Skytrofa) demonstrated non-inferior height velocity versus daily somatropin in treatment-naive pediatric GHD; supported FDA approval in 2021.
• Weekly somapacitan adult GHD (Johannsson et al., J Clin Endocrinol Metab 2020; PMID 32072187) — REAL1 phase 3 trial: somapacitan once-weekly non-inferior to daily somatropin on IGF-1 and body-composition endpoints. FDA approval 2020 (Sogroya).
• AIDS-associated wasting (Serostim) — rhGH 0.1 mg/kg/day (capped at 6 mg/day) approved in 1996 for AIDS-associated catabolic states; FDA approval based on lean-body-mass recovery in wasting patients. Modern antiretroviral therapy has substantially reduced the patient population for this indication.
• Short bowel syndrome (Zorbtive) — Higher-dose rhGH 0.1 mg/kg/day up to 8 mg/day approved 2003 as adjunctive therapy with specialized nutritional support for short bowel syndrome.
• KIGS pediatric safety (Wilton et al., J Pediatr 2010; PMID 20728892) — Long-term safety data from the Kabi/Pfizer International Growth Study pediatric registry — >80,000 children-years of rhGH therapy; no increase in leukemia or second-cancer incidence beyond predisposing conditions.
• SAGhE long-term mortality signal (Sävendahl et al., J Clin Endocrinol Metab 2012; PMID 22259051) — European multinational observational cohort identified a small but statistically significant increase in cerebrovascular and all-cause mortality among adults treated with rhGH as children for isolated idiopathic GH deficiency or short stature — a signal that has informed cautious-dose practice patterns since. Interpretation is debated due to observational design and historical dosing exceeding modern practice.
• Cancer risk — epidemiologic IGF-1 — Elevated serum IGF-1 in the upper reference range is epidemiologically associated with increased risk of colorectal, prostate, and breast cancers (Pollak, Nat Rev Cancer 2012; PMID 22473468). GH therapy itself has not been conclusively linked to excess cancer incidence in prospective trial cohorts, but keeping IGF-1 within the age-appropriate reference range — rather than supraphysiologic — is the clinical prudence principle.

Human Data

The following are representative pivotal, post-marketing, and systematic-review references across rhGH's four decades of clinical use.

• Rudman et al., NEJM 1990 (PMID 2355952) — 12-subject 6-month RCT; 8.8% lean-mass gain, 14.4% fat-mass reduction in older men. The foundational anti-aging reference.
• Molitch et al., JCEM 2011 (PMID 21543432) — Endocrine Society adult GHD clinical practice guideline; diagnosis, treatment, and monitoring framework.
• Liu et al., Ann Intern Med 2007 (PMID 17200260) — Systematic review of anti-aging rhGH; modest body-composition benefit without functional gains; increased adverse events.
• Johannsson et al., JCEM 2020 (PMID 32072187) — REAL1 phase 3 trial of weekly somapacitan for adult GHD.
• Thornton et al., JCEM 2021 — heiGHt phase 3 trial of weekly lonapegsomatropin in pediatric GHD.
• Wilton et al., J Pediatr 2010 (PMID 20728892) — KIGS long-term pediatric safety registry.
• Sävendahl et al., JCEM 2012 (PMID 22259051) — SAGhE long-term mortality signal in childhood-GH-treated adults.
• Growth Hormone Research Society / Consensus Statements — Periodic international consensus on diagnosis and treatment of adult and childhood GHD; most recent updates via JCEM consensus papers.
• Kaplan et al., NEJM 1985 — Original approval-supporting Protropin pediatric GHD trial.
• Mauras et al., J Pediatr 2000 (PMID 10969269) — Dose-response of GH in pediatric ISS.
• Grinspoon et al. AIDS wasting pivotal trials — Basis of Serostim 1996 FDA approval for AIDS-associated catabolism.
• Seguro et al. short bowel syndrome pivotal trial — Basis of Zorbtive 2003 FDA approval.

Dosing from the Literature

rhGH dosing is indication-specific and follows a weight-based (pediatric) or IGF-1-titrated (adult) pattern. Dose is expressed in milligrams (older clinical literature and some pen devices use IU; 1 mg ≈ 3 IU for modern recombinant somatropin).

Reconstitution & Storage

Modern rhGH is supplied in pen devices with pre-formulated cartridges or lyophilized powder with a matched diluent. Each brand has product-specific storage and stability characteristics; the following summarizes typical US formulations.

• Reconstitution (lyophilized powders) — Inject diluent slowly down the vial wall at 45°. Swirl gently; do not shake. Clear and colorless solution expected. Discard if cloudy or showing particulate.
• Pen devices — Prime the pen before each use per manufacturer instructions; dial the prescribed dose; inject at the selected SubQ site; rotate sites to minimize lipohypertrophy.
• Injection sites — Abdomen (avoiding umbilical zone), thigh, upper outer arm, upper-outer buttock. Rotate weekly.
• Needles — 31G–32G 5–8 mm pen needles for SubQ; use a fresh needle for each injection.
• Travel — Insulated cool pack with ice-pack maintains refrigeration; in-use pen can be out of refrigeration briefly per label. Never freeze.
• Timing — Evening / bedtime SubQ is conventional to align with the physiologic nocturnal GH pulse; morning dosing is acceptable if preferred for adherence.
• Mixed dosing — Do not mix rhGH with insulin, testosterone, or other medications in the same syringe.

→ Use the Kalios Dosing Calculator for IU-to-mg conversions and pen-device math

Side Effects & Risks

rhGH's side-effect profile is among the best-characterized in pharmacology — the result of four decades of controlled clinical use and extensive post-marketing surveillance. Most adverse events are dose-dependent and largely reversible upon dose reduction or discontinuation.

• Soft tissue edema / fluid retention — The single most common early adverse event. Puffy hands, face, and ankles; weight gain of 1–2 kg in the first month from extracellular-fluid expansion. Dose-dependent; typically stabilizes or resolves with dose reduction.
• Arthralgia and myalgia — Joint and muscle aches; most common in first weeks of therapy, often improves over months. Dose-dependent.
• Carpal tunnel syndrome — Edema-mediated median nerve compression. Reversible with dose reduction or cessation. One of the most common reasons for discontinuation in adult GHD replacement.
• Impaired glucose tolerance / insulin resistance — GH's counter-regulatory action raises fasting glucose and insulin. Clinically significant progression to overt diabetes is uncommon at replacement doses but well-documented at supraphysiologic doses. Monitor fasting glucose, insulin, and HbA1c.
• Gynecomastia — Occasional; attributed to GH-mediated increase in IGF-1 and indirect estrogen-axis effects. More common in adult men on higher doses.
• Intracranial hypertension (pseudotumor cerebri) — Rare; reversible with dose reduction. Presents with headache, visual change, papilledema. Labeled precaution across all rhGH products.
• Scoliosis progression (pediatric) — rhGH can accelerate growth of existing scoliosis; does not cause de novo scoliosis. Monitor pediatric patients with known scoliosis.
• Slipped capital femoral epiphysis (SCFE) — Rare pediatric complication. Investigate new hip / knee pain on therapy.
• Adrenal insufficiency unmasking — rhGH increases cortisol clearance by downregulating 11β-HSD1. Patients with borderline adrenal reserve may become frankly insufficient on rhGH — screen before initiation in suspected cases.
• Hypothyroidism unmasking — GH influences T4-to-T3 conversion and can unmask central or primary hypothyroidism. Monitor thyroid function at baseline and during therapy.
• Cancer risk (epidemiologic) — Circulating IGF-1 in the upper reference range is epidemiologically associated with increased colorectal, prostate, and breast cancer risk (Pollak 2012). GH therapy itself has not been conclusively linked to excess cancer incidence in prospective cohorts, but pre-existing malignancy is a labeled contraindication and IGF-1-guided dosing rather than supraphysiologic targeting is the clinical prudence principle.
• Cardiac hypertrophy (high-dose chronic) — Supraphysiologic chronic GH (bodybuilding doses) is associated with left-ventricular hypertrophy and cardiomyopathy in acromegaly and in high-dose non-medical users. Not a signal at replacement doses.
• Visceral organ growth ("GH gut") — Supraphysiologic GH + insulin + IGF-1 protocols in bodybuilding are associated with visceral organ growth and abdominal protrusion. Not a replacement-dose phenomenon.
• Injection-site reactions — Local redness, pruritus, lipohypertrophy at chronic single-site injection. Site rotation prevents.
• WADA-banned (S2) — Human growth hormone is prohibited at all times under WADA category S2 (peptide hormones). Detection methods include immunoassay isoform ratios (pituitary vs recombinant) and biomarker panels (P-III-NP / IGF-1). Not viable for tested athletes.
• Anabolic Steroid Control Act (21 USC §333(e)) — Non-medical distribution of human growth hormone is a federal crime, punishable by up to 5 years imprisonment (10 years if distribution to a person under 18). Legitimate clinician-prescribed rhGH for an FDA-approved or off-label medical indication within a clinician-patient relationship is lawful; distribution outside that framework is not.
• Drug interactions — rhGH alters insulin, oral hypoglycemic, corticosteroid, and thyroid-hormone requirements. Estrogen therapy reduces rhGH response (oral estrogen in particular), requiring higher rhGH doses for equivalent IGF-1.

Bloodwork & Monitoring

rhGH therapy is IGF-1-guided, not dose-fixed. Monitoring follows Endocrine Society and GH Research Society consensus.

• IGF-1 (age- and sex-specific) — The primary monitoring marker. Target upper half of age-specific reference range (SD 0 to +2) in replacement therapy; not supraphysiologic. Check at baseline, 4–6 weeks after any dose change, then quarterly.
• IGFBP-3 — Adjunct to IGF-1 in some protocols; forms the circulating 150 kDa complex with IGF-1 and ALS. Useful for cross-validation of IGF-1 measurement.
• Fasting glucose and HbA1c — Standard metabolic monitoring; GH is insulin-antagonistic. Baseline and quarterly on therapy.
• Fasting insulin / HOMA-IR — More sensitive than fasting glucose alone for early insulin resistance. Useful in adult GHD and anti-aging protocols.
• TSH, free T4, free T3 — Baseline and periodic; GH can unmask central or primary hypothyroidism.
• Morning cortisol / ACTH stimulation — Baseline assessment in adult GHD (to exclude co-existing adrenal insufficiency) and annually on chronic therapy; GH therapy can unmask borderline adrenal insufficiency.
• PSA (men >40) — Baseline and annually; IGF-1 epidemiology warrants prostate surveillance during any IGF-1-elevating therapy.
• Mammogram — Age-appropriate; IGF-1 epidemiology warrants breast surveillance in women.
• Colonoscopy — Age-appropriate and family-history-adjusted; IGF-1 and colorectal cancer epidemiology.
• Lipid panel — Baseline and periodic; adult GHD replacement typically improves lipid profile (LDL down, HDL up modestly).
• DEXA body composition — Baseline and annual in adult replacement; quantifies lean mass, fat mass, visceral fat change.
• DEXA bone density — Baseline and at 1–2 year intervals in adult GHD replacement.
• Pituitary MRI — At diagnosis of adult GHD to exclude pituitary mass lesion; not a therapy-monitoring tool.
• Echocardiography — At baseline in high-dose / supraphysiologic protocols; not standard at replacement doses.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching HGH often also look at these:

Next Steps

Key References

1. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990;323(1):1-6. PMID: 2355952. (The landmark anti-aging reference.)
2. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML; Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587-1609. PMID: 21543432.
3. Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, Hoffman AR. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104-115. PMID: 17200260. (The most-cited independent appraisal of anti-aging rhGH.)
4. Johannsson G, Gordon MB, Højby Rasmussen M, Håkonsson IH, Karges W, Sværke C, Tahara S, Takano K, Biller BMK. Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial. J Clin Endocrinol Metab. 2020;105(4):e1358-e1376. PMID: 32072187. (REAL1 — basis of 2020 Sogroya approval.)
5. Brown RJ, Adams JJ, Pelekanos RA, Wan Y, McKinstry WJ, Palethorpe K, Seeber RM, Monks TA, Eidne KA, Parker MW, Waters MJ. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol. 2005;12(9):814-821. PMID: 15834426.
6. Wilton P, Mattsson AF, Darendeliler F. Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database). J Pediatr. 2010;157(2):265-270. PMID: 20728892.
7. Sävendahl L, Maes M, Albertsson-Wikland K, Borgström B, Carel JC, Henrard S, Speybroeck N, Thomas M, Zandwijken G, Hokken-Koelega A. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab. 2012;97(2):E213-E217. PMID: 22259051.
8. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12(3):159-169. PMID: 22473468. (IGF-1 and cancer epidemiology — central safety-framing source.)
9. Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J; Genentech, Inc Cooperative Study Group. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. J Clin Endocrinol Metab. 2000;85(10):3653-3660. PMID: 11061517.
10. Grinspoon S, Mulligan K; Department of Health and Human Services Working Group on the Prevention and Treatment of Wasting and Weight Loss. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003;36(Suppl 2):S69-S78. PMID: 12652374. (Context for Serostim / AIDS-wasting indication.)
11. Cook DM, Yuen KC, Biller BM, Kemp SF, Vance ML; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients — 2009 update. Endocr Pract. 2009;15(Suppl 2):1-29. PMID: 20228036.
12. Powers ME. The safety and efficacy of anabolic steroid precursors: what is the scientific evidence? J Athl Train. 2002;37(3):300-305. PMID: 12937588. (Context for Anabolic Steroid Control Act and GH legal framework.)
13. U.S. Food and Drug Administration. Genotropin (somatropin) Prescribing Information. Pfizer Inc.
14. U.S. Food and Drug Administration. Norditropin (somatropin) Prescribing Information. Novo Nordisk Inc.
15. U.S. Food and Drug Administration. Sogroya (somapacitan) Prescribing Information. Novo Nordisk. First approved 2020.
16. U.S. Food and Drug Administration. Skytrofa (lonapegsomatropin-tcgd) Prescribing Information. Ascendis Pharma. First approved 2021.
17. 21 U.S.C. §333(e) — Anabolic Steroid Control Act, human growth hormone provision. U.S. Code.
18. WADA. 2026 World Anti-Doping Code Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. (rhGH S2 prohibition and detection methods.)